Chimerix (CMRX) Scheduled to Post Quarterly Earnings on Thursday

Chimerix (NASDAQ:CMRX) is scheduled to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting analysts’ consensus estimates of ($0.23). The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $1.26 million. During the same quarter last year, the firm earned ($0.21) earnings per share. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chimerix Stock Performance

NASDAQ:CMRX opened at $0.99 on Friday. The stock has a 50-day simple moving average of $0.90 and a 200 day simple moving average of $0.91. Chimerix has a 52-week low of $0.75 and a 52-week high of $1.30. The company has a market cap of $88.74 million, a PE ratio of -1.04 and a beta of 1.12.

Wall Street Analysts Forecast Growth

CMRX has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Chimerix in a research note on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research report on Tuesday, August 13th. Finally, StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.